MindWalk (NASDAQ:HYFT) Raised to “Hold” at Zacks Research

MindWalk (NASDAQ:HYFT) was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a note issued to investors on Monday, Zacks reports.

A number of other research firms have also commented on HYFT. Wall Street Zen upgraded MindWalk from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. HC Wainwright reaffirmed a “buy” rating on shares of MindWalk in a research report on Monday, July 20th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of MindWalk in a report on Wednesday, July 15th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $5.00.

MindWalk Trading Up 0.7%

Shares of NASDAQ HYFT opened at $1.48 on Monday. The firm’s 50 day moving average price is $1.36 and its 200-day moving average price is $1.37. MindWalk has a 52-week low of $0.99 and a 52-week high of $2.99. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.75 and a current ratio of 1.84. The company has a market cap of $69.13 million, a PE ratio of -5.69 and a beta of 0.82.

MindWalk (NASDAQ:HYFT) last announced its quarterly earnings data on Monday, September 14th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.04). The firm had revenue of $2.73 million during the quarter, compared to analysts’ expectations of $3.25 million. MindWalk had a negative return on equity of 133.26% and a negative net margin of 105.11%. On average, equities research analysts expect that MindWalk will post -0.21 EPS for the current fiscal year.

Institutional Trading of MindWalk

A hedge fund recently bought a new position in MindWalk stock. BlackRock Inc. purchased a new position in MindWalk Holdings Corp. (NASDAQ:HYFT) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 154,411 shares of the company’s stock, valued at approximately $244,000. BlackRock Inc. owned 0.33% of MindWalk at the end of the most recent quarter. Hedge funds and other institutional investors own 6.70% of the company’s stock.

About MindWalk

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.